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Abstract
Objective
To report outcomes on patients with multiple sclerosis (MS) and related disorders with
coronavirus disease 2019 (COVID-19) illness.
Methods
From March 16 to April 30, 2020, patients with MS or related disorders at NYU Langone MS
Comprehensive Care Center were identiﬁed with laboratory-conﬁrmed or suspected COVID19. The diagnosis was established using a standardized questionnaire or by review of in-patient
hospital records.
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Results
We identiﬁed 76 patients (55 with relapsing MS, of which 9 had pediatric onset; 17 with
progressive MS; and 4 with related disorders). Thirty-seven underwent PCR testing and were
conﬁrmed positive. Of the entire group, 64 (84%) patients were on disease-modifying therapy
(DMT) including anti-CD20 therapies (n = 34, 44.7%) and sphingosine-1-phosphate receptor
modulators (n = 10, 13.5%). The most common COVID-19 symptoms were fever and cough,
but 21.1% of patients had neurologic symptom recrudescence preceding or coinciding with the
infection. A total of 18 (23.7%) were hospitalized; 8 (10.5%) had COVID-19 critical illness or
related death. Features more common among those hospitalized or with critical illness or death
were older age, presence of comorbidities, progressive disease, and a nonambulatory status. No
DMT class was associated with an increased risk of hospitalization or fatal outcome.
Conclusions
Most patients with MS with COVID-19 do not require hospitalization despite being on DMTs.
Factors associated with critical illness were similar to the general at-risk patient population.
DMT use did not emerge as a predictor of poor COVID-19 outcome in this preliminary sample.
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Glossary
CAD = coronary artery disease; COVID-19 = coronavirus disease 2019; DMT = disease-modifying therapy; ICU = intensive
care unit.

At present, we do not know whether multiple sclerosis
(MS) or disease-modifying therapies (DMTs) for MS increase the risk of acquiring coronavirus disease 2019
(COVID-19) or worsen the course (hospitalizations, intensive care unit [ICU], and death). DMT medications
have immunosuppressive eﬀects that could hamper
mounting an eﬀective immune response to the infection.1
On the other hand, immunosuppression could oﬀer protection by downregulating hyperinﬂammation and the cytokine storm associated with COVID-19.2
New York City emerged as the epicenter of the COVID-19
pandemic in the United States in March 2020. Given the
widespread prevalence of COVID-19 in our community,
clinicians at the NYU Multiple Sclerosis Comprehensive Care
Center (MSCCC) received numerous reports of Severe Acute
Respiratory Syndrome Coronavirus 2 (SARS-COV2) infection
from patients and began systematically collecting symptom
data and the clinical course. This timely, real-world observational study on outcomes of COVID-19 in actively treated
patients with MS help inform clinicians as they counsel patients
with MS and guide treatment decisions during the pandemic.

Methods
For this observational study, demographic and clinical features were collected on patients currently followed at
MSCCC and its 4 aﬃliated sites in the greater New York area
(2 in Long Island and 2 in Brooklyn) with a history of
COVID-19 from March 16 through April 30, 2020. All
patients who contacted the center with infectious symptoms
or were seen during routine teleneurology visits were queried
regarding COVID-19 exposure using a standardized instrument. Inclusion criteria were any patient with MS or related disorders who was diagnosed with COVID-19 by
a health care provider (based on symptoms, course, radiographic ﬁndings consistent with CDC COVID-19 criteria,3
and/or positive SARS-COV2 PCR when available). For
hospitalized patients, in-patient records were reviewed. NYU
School of Medicine Institutional Review Board approval was
obtained for the study.
Descriptive statistics were used to summarize the demographic and clinical characteristics of patient. Continuous
variables were described in terms of means and SDs, and
categorical variables were summarized as counts and percentages. No imputation was made for missing data. Diﬀerences between hospitalized vs nonhospitalized patients were
compared by the t test, χ 2 test, or Fisher exact test as indicated,
with CIs set at 95%.
2

Data availability
Anonymized data can be made available on request for research
purposes by submitting a request to the corresponding author. No
deidentiﬁed patient data or study-related documents will be shared.

Results
A total of 76 patients met the inclusion criteria, 72 (93%)
with MS, and 4 (7%) with related disorders (neuromyelitis
optica spectrum disorder, chronic relapsing inﬂammatory optic
neuropathy, neurosarcoidosis, and myelin oligodendrocyte
glycoprotein-immunoglobulin G–associated disorder). The
average age of the full sample was 44.9 ± 15.2 years (range
13–71 years), and 61.8% were female. The disease duration was
15.2 ± 10.7 years (range 1–52 years). Racial breakdown was 50
(65.8%) white, 21 (27.6%) black, 3 (3.9%) Asian, 1 (1.3%)
Paciﬁc Islander, and 1 (1.3%) other. Hispanic ethnicity was
reported by 15 (19.7%). Of the 72 patients with MS, 55
(76.4%) had a relapsing-remitting subtype and 17 (23.6%)
primary or secondary progressive subtypes. Sixty-ﬁve patients
(84%) were on DMT. One patient resided in a nursing facility.
He had an uncomplicated course.
Common symptoms reported included fever (68.4%), cough
(68.4%), fatigue (38.2%), shortness of breath (31.6%), and
myalgias/arthralgias (26.3%). Other frequent symptoms included anosmia (22%), ageusia (19.7%), and headache
(21.1%). A subset reported neurologic symptom recrudescence
(21.1%) suggestive of relapse. In some cases, neurologic
symptoms preceded viral symptoms by several days.
Of the 84% of patients on DMTs, 44.7% were treated with antiCD20 therapies (rituximab n = 18; ocrelizumab n = 16), 13.5%
on sphingosine-1-phosphate (S1P) modulators (ﬁngolimod n
= 8; siponimod n = 2), 7.9% (n = 6) on glatiramer acetate, 5.3%
(n = 4) each on natalizumab and dimethyl fumarate, and 3.9%
(n = 3) on beta-interferons. Table 1 summarizes outcomes by
DMT class. There were no observed diﬀerences between DMT
use among those who were and were not hospitalized or between those speciﬁcally treated with anti-CD20 therapies (43%
vs 50%, OR = 0.76 [CI 0.26–2.18]).
As shown in table 2, of the full sample, 18 (23.7%) were hospitalized. The hospitalized vs nonhospitalized patients were more
likely to be older (CI 1.22–17.11, p = 0.03), have progressive MS
subtype (OR 4.11 [CI 1.21–13.97], p = 0.04), required ambulatory assistance or were nonambulatory (OR 4.27 [CI 1.38–13.27],
p = 0.01), and have comorbid obesity (OR 6.25 [CI 1.90–20.50],
p = 0.003). Coronary artery disease (CAD) was observed in n = 3
hospitalized patients and no cases in nonhospitalized patients.
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Table 1 Disease-modifying therapy specific outcomes
Demographics

Anti-CD20

S1P inhibitors

Glatiramer acetate

Natalizumab

Dimethyl fumarate

Interferon

IVIG

None

n

34

10

6

4

4

3

3

12

Age, years (SD)

38.72 (SD 14.9)

44.90 (SD 11.2)

53.3 (SD 14.8)

37.8 (SD 17.9)

52.8 (SD 7.2)

57.6 (SD 16.7)

57 (SD 12.8)

49.8 (SD 15.8)

Female n (%)

20 (62.5%)

6 (60%)

4 (66.7%)

2 (50%)

2 (50%)

1 (33.3%)

3 (100%)

8 (66.7%)

Ambulatory

27 (79.4%)

9 (90%)

2 (33.3%)

4 (100%)

3 (75%)

3 (100%)

—

8 (66.7%)

Ambulatory with assistance

4 (11.8%)

1 (10%)

3 (50%)

—

—

—

2 (66.7%)

1 (8.3%)

Nonambulatory

3 (8.8%)

—

1 (16.7%)

—

1 (25%)

—

1 (33.3%)

3 (25%)

Not hospitalized

25 (73.5%)

9 (90%)

5 (83.3%)

3 (75%)

2 (50%)

3 (100%)

3 (100%)

8 (66.7%)

Hospitalized

9 (26.5%)

1 (10%)

1 (16.7%)

1 (25%)

2 (50%)

—

—

4 (33.3%)

Obesity

9 (26.5%)

3 (30%)

2 (33.3%)

2 (50%)

1 (25%)

—

1 (33.3%)

6 (50%)

Hypertension

4 (11.8%)

3 (30%)

1 (16.7%)

1 (25%)

2 (50%)

—

2 (66.7%)

4 (33.3%)

Diabetes

1 (2.9%)

1 (10%)

1 (16.7%)

1 (25%)

1 (25%)

—

1 (33.3%)

2 (16.7%)

CAD

1 (2.9%)

—

1 (16.7%)

1 (25%)

—

—

—

—

Death

2 (5.8%)

—

1 (16.7%)

1 (25%)

—

—

—

2 (16.7%)

Ongoing treatment/still recovering

8 (23.5%)

3 (30%)

1 (16.7%)

—

—

—

1 (33.3%)

2 (16.7%)

Recovered

24 (70.6%)

7 (70%)

4 (66.7%)

3 (75%)

4 (100%)

3 (100%)

2 (66.7%)

8 (66.7%)

Ambulation status, n (%)
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Hospitalization

Comorbidities associated with COVID-19

COVID-19 outcomes

Abbreviations: Anti-CD20 = ocrelizumab and rituximab; COVID-19 = coronavirus disease 2019; Interferons = interferon beta-1a and interferon beta-1b; IVIG = IV immunoglobulins; S1P inhibitors = fingolimod and siponimod.
One 58-year-old woman with a history of hypertension on leflunomide had a mild course.
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Table 2 Demographics of hospitalized vs nonhospitalized patients with COVID-19
Demographics

Hospitalized (n = 18)

Nonhospitalized (n = 58)

Age, years (range, SD)

52.0 (17–71, 14.6)

42.7 (13–71, 14.8)

Sex (% female)

10 (55.6%)

37 (63.8%)

Race, n (% white)

12 (66.7%)

38 (65.5%)

Ethnicity, n (% Hispanic)

6 (33.3%)

9 (15.5%)

RRMS

8 (44.4%)

47 (81.0%)

Progressive MS

7 (38.8%)

10 (17.2%)

Other demyelinating syndrome

3 (16.7%)

1 (1.7%)

Disease duration, years (range, SD)

17.2 (5–36, 10.5)

14.6 (1–52, 10.8)

Ambulatory

9 (50%)

47 (81%)

Ambulatory with assistance

5 (27.8%)

6 (10.3%)

Nonambulatory

4 (22.2%)

5 (8.6%)

Obesity

11 (61%)

12 (20.7%)

Hypertension

5 (27.8%)

12 (20.6%)

CAD

3 (16.6%)

—

Diabetes

2 (11.1%)

6 (10.3%)

Venous thromboembolism

3 (16.6%)

1 (1.7%)

Death, n (%)

5 (27.7%)

1 (1.7%)

Ongoing treatment/still recovering

4 (22.2%)

10 (17.2%)

Recovered, n (%)

9 (50.0%)

47 (81.0%)

Clinical diagnosis

Ambulation status, n (%)

Comorbidities associated with COVID-19

COVID-19 outcomes

Abbreviations: CAD = coronary artery disease; COVID-19 = coronavirus disease 2019; DMT = disease-modifying therapy.

History of venous thromboembolism was recorded in n = 3
hospitalized and n = 1 nonhospitalized patient.
Eight patients (10.5%) had critical illness deﬁned by ICU admission (n = 5) and/or death (n = 6) (table 3). Compared with the
entire MS sample, the critically ill patients were older (mean of 57.7
± 10.5 years, range 42–71 years), more likely to have a progressive
subtype (50.0%), and or required assistance for ambulation/
nonambulatory (62.5% requiring assistance or nonambulatory).
Following the pattern observed in those who were hospitalized, the
critically ill group had had high rates of comorbid obesity (62.5%),
CAD (25%), and venous thromboembolism (37.5%). There were
no reports of stroke. One patient had hypercoagulability resulting
in multiple venous thromboembolisms and ultimately died.
Nine patients with pediatric-onset MS were identiﬁed as the
center has a large pediatric MS sample (table 4). Ages
ranged from 13 to 26 years; 8 were female, and all had
4

relapsing-remitting MS. Noted comorbidities were obesity
(n = 3), type I diabetes (n = 1), or both (n = 1). Two of the 9
were hospitalized requiring supplemental oxygen. None
required invasive ventilation. Eight patients were either fully
recovered or recovering at censoring date. One remains
hospitalized.

Discussion
Patients with MS and related disorders often seek guidance
regarding the impact of the disease and medication on their
risk of COVID-19. This observational study—although subject to sampling and ascertainment biases—provides some
insights regarding COVID-19 disease course in actively
treated patients with MS and related disorders.
The rate of hospitalization in our patients (24%) and mortality (7.9%) are in line with the data of another published MS
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Table 3 Critically ill and deceased patient outcomes
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Diagnosis and
disease duration
(y)

DMT

Ambulation
status

Black/nonHispanic

RRMS—18 y

Rituximab

46/
M

Black/nonHispanic

SPMS—26 y

50/F

White/nonHispanic

60/F

Age/
sex

Race/
ethnicity

42/
M

Comorbidities

COVID course and outcome

Nonambulatory

Chronic anticoagulation for VTE, Hodgkin
lymphoma, and ITB

Several weeks of fevers, cough, and dyspnea. A family member in the home
was also sick with similar symptoms. Died at home.

None

Nonambulatory

Diabetes, morbid obesity, hypertension, chronic
anticoagulation for VTE, and hyperlipidemia

Hospitalized with dyspnea, fever, and cough and received high-flow oxygen.
Discharged to a rehabilitation facility on supplemental oxygen

RRMS—13 y

None

Ambulatory

Hypertension, obesity, and hypothyroid

Hospitalized with respiratory failure following treatment with 5 d of IVMP for
MS exacerbation. Received ventilator and ECMO support. Deceased.

Black/nonHispanic

RRMS—19 y

Natalizumab

Ambulatory

CAD with cardiac stents, hypertension, and obesity

Hospitalized with fatigue, cough, fever, and respiratory failure. Found to have
DVT and PE. Had cardiac arrest. Deceased.

62/
M

White/
Hispanic

NMOSD—7 y

Rituximab

Ambulatory

Obesity

Hospitalized with dyspnea and fever and on high-flow oxygen. Remains
hospitalized.

65/F

White/nonHispanic

SPMS—31 y

None

Nonambulatory

ITB and neurogenic bladder with indwelling Foley

Hospitalized with fever, dyspnea, and code status DNR/DNI. Deceased

66/
M

White/nonHispanic

SPMS—33 y

Ocrelizumab

Nonambulatory

Remote history of testicular and prostate cancer
and ITB

Hospitalized with respiratory failure and received ventilator support.
Deceased.

71/
M

Black/nonHispanic

SPMS—30 y

Glatiramer
acetate

Ambulatory
with assistance

Chronic anticoagulation for VTE obesity

Hospitalized with dyspnea and fever and had cardiac arrest. Deceased.

Abbreviations: CAD = coronary artery disease; COVID-19 = coronavirus disease 2019; DMT = disease-modifying therapy; DNR/DNI = do not resituate/do not intubate; DVT = deep venous thrombosis;
ECMO = extracorporeal membrane oxygenation; ITB = intrathecal baclofen pump; IVMP = IV methylprednisolone; PE = pulmonary embolus; RRMS = relapsing-remitting MS; SPMS = secondary progressive MS; VTE =
venous thrombosis.
Of the 8 patients, 7 tested positive for COVID-19. The patient who died at home was not tested for COVID as he did not receive any hospital care before expiration. Both he and a family member he resided with had symptoms of
fever, cough, and dyspnea for several weeks prior. The family member has since recovered.
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Table 4 Demographics of patients with pediatric-onset
MS with COVID-19
Full sample
(n = 9)
Demographics
Age, years (range, SD)

19.44 (13–26,
4.12)

Sex (% female)

7 (77.7%)

Race, n (% white)

6 (66.6%)

Ethnicity, n (% Hispanic)

5 (55.5%)

Clinical history
MS subtype, n (% RRMS)

9 (100%)

Disease duration, years (range, SD)

6.11 (2–12, 3.55)

DMT, n (%)
Glatiramer

1 (11.1%)

Ocrelizumab

2 (22.2%)

Rituximab

4 (44.4%)

Natalizumab

1 (11.1%)

None

1 (11.1%)

Ambulation status, n (% fully ambulatory)

9% (100)

COVID-19 testing, comorbidities, and
hospitalization
Tested for COVID-19, n (%)

5 (55.5%)

Positive, n (% tested)

4 (80%)

Diabetes, type I

2 (22.2%)

Obesity

3 (33.3%)

Asthma

1 (11.1%)

Hospitalized, n (%)

2 (22.2%)

Abbreviation: DMT = disease-modifying therapy.

patient survey4 and for the general population of patients
with COVID-19.5 Similar risk factors were identiﬁed including older age, male sex, and high number of comorbidities such as obesity, diabetes, hypertension, and
CAD.6–8 MS-speciﬁc features associated with more severe
COVID-19 included nonambulatory status and progressive disease course. Given the small sample size, we
could not determine whether these patients were at higher
risk, given their advanced age and other comorbidities, or
whether worse disability in and of itself represents an additional risk factor.
We did not observe an association between DMT class and
COVID-19 outcome in univariate comparisons; however, our
sample size is small, and these preliminary ﬁndings should be
interpreted with caution. There is a relatively high proportion
6

of COVID-19–infected patients on anti-CD20 therapies
(44.7%) compared with our MSCCC population in which
33.1% of patients take anti-CD20 therapies. This observation
could be an artifact of sampling bias or might represent an
increased susceptibility to COVID-19 infection as anti-CD-20
therapies increase the risk of non-COVID-19 infections in
general.1 It is worth noting that although we had a larger-thanexpected portion of patients on anti-CD20 therapies, there is
no evidence to suggest worse outcomes.
As a note of caution in the care of patients with MS, a subgroup of individuals reported worsening of preexisting neurologic symptoms before or at onset of COVID-19 symptoms.
One such patient was treated with several days of high-dose
steroids after which they presented with respiratory and circulatory failure and ultimately died (table 3). Infections are
a well-known cause of pseudoexacerbations, and in areas with
high prevalence of COVID-19, testing for SARS-COV2
should be considered in patients with acute worsening of
preexisting symptoms before steroid treatment is initiated.
Our study has several limitations. This was a convenience
sample and not randomly selected, nor was the entire practice
systematically surveyed. Patients were identiﬁed during routine
teleneurology visits, if they notiﬁed the oﬃce, or if
hospitalized—likely leading to an overrepresentation of more
symptomatic individuals. Patients on higher potency infusible
DMTs were more likely to have frequent follow-up and may
have been more readily captured. In contrast, patients in nursing
homes, who would be expected to be most severely aﬀected by
COVID-19, visit specialized centers less frequently and could be
underrepresented in our cohort. Although we used a systematic
questionnaire to collect relevant data, we could not verify these
data independently unless the patient was seen by an NYU
Langone-aﬃliated physician or hospital. Another problem was
lack of access to COVID-19 testing in our area. Less than half of
our patients (48.7%) underwent SARS-COV2 PCR testing. As
shown in table 5, subgroup analysis showed that this group was
not diﬀerent from the overall sample with respect to demographic or MS-related features.
Our early experience with COVID-19 at NYU Langone
MSCCC could inform clinicians taking care of patients with MS
during the pandemic. Our ﬁndings suggest that individuals with
MS who experience COVID-19 have similar disease course,
outcomes, and risk factors for complications as the general
population. Rigorous, population-based studies are needed to
conﬁrm our preliminary ﬁndings and better deﬁne the risk of
COVID-19 infection with respect to individual DMTs. Future
studies should assess the role of baseline lymphocyte counts and
immunoglobulin levels with respect to viral susceptibility and
course as well as examine the frequency of serologies to
COVID-19 according to DMT class. As we and others collect
more data and contribute to larger MS registries, we expect
more answers will be forthcoming to further guide patient
management.
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Table 5 Demographics and outcomes of all patients vs COVID-19 PCR confirmed positive
All patients (n = 76)

COVID PCR positive (n = 37)

Age, years (range, SD)

44.9 (13–71, 15.2)

47.5 (13–71, 15.15)

Sex, F/M (% female)

47/29 (61.8%)

23/14 (62.2%)

White

50 (65.8%)

24 (64.9%)

Black

21 (27.6%)

12 (32.4%)

Asian

3 (3.9%)

—

Pacific Islander

1 (1.3%)

—

Other

1 (1.3%)

1 (2.7%)

Non-Hispanic

59 (77.6%)

28 (75.7%)

Hispanic

15 (19.7%)

8 (21.6%)

Other

2 (2.6%)

1 (2.7%)

Never

52 (68.4%)

25 (67.5%)

Former

20 (26.3%)

10 (27.02)

Current

2 (2.6%)

1 (2.7%)

Unknown

2 (2.6%)

1 (2.7%)

RRMS

55 (72.3%)

25 (67.6%)

SPMS

15 (19.7%)

10 (27.0%)

PPMS

2 (2.6%)

—

Other demyelinating syndrome, n (%)

4 (5.2%)

2 (5.4%)

Disease duration, years (range, SD)

15.2 (1–52, 10.7)

16.9 (2–52, 11.46)

Anti-CD20

34 (44.7%)

14 (37.8%)

S1P Inhibitors

10 (13.2%)

4 (10.8%)

Glatiramer acetate

6 (7.9%)

4 (10.8%)

Natalizumab

4 (5.3%)

3 (8.1%)

Dimethyl fumarate

4 (5.3%)

2 (5.4%)

Leflunomide

1 (1.3%)

1 (2.7%)

Interferons

3 (3.9%)

1 (2.7%)

IVIG

3 (3.9%)

1 (2.7%)

None

12 (15.8%)

7 (18.9%)

Ambulatory

56 (73.7%)

24 (64.9%)

Ambulation with assistance

11 (14.4%)

7 (18.9%)

Demographics

Race, n (%)

Ethnicity, n (%)

Smoking status, n (%)

Clinical
MS, n (%)

DMT, n (%)

Ambulation status, n (%)

Continued

Neurology.org/NN
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Table 5 Demographics and outcomes of all patients vs COVID-19 PCR confirmed positive (continued)
All patients (n = 76)

COVID PCR positive (n = 37)

9 (11.8%)

6 (16.2%)

Hypertension

17 (22.4%)

11 (29.7%)

Obesity

23 (30.3%)

11 (29.7%)

Diabetes

8 (10.5%)

5 (13.5%)

VTE

4 (5.3%)

3 (8.1%)

CAD

3 (3.9%)

3 (8.1%)

History of cancer

4 (5.3%)

2 (5.4%)

Baclofen pump

3 (3.9%)

2 (5.4%)

Indwelling Foley

3 (3.9%)

2 (5.4%)

None

24 (31.6%)

12 (32.4%)

Death, n (%)

6 (7.9%)

5 (13.5%)

Ongoing treatment/still recovering

14 (18.4%)

7 (18.9%)

Recovered, n (%)

56 (73.7%)

25 (67.6%)

Nonambulatory
Comorbidities associated with COVID-19

COVID-19 outcomes

Abbreviations: Anti-CD20 = ocrelizumab and rituximab; CAD = coronary artery disease; COVID-19 = coronavirus disease 2019; DMT = disease-modifying
therapy; Interferons = interferon beta-1a and interferon beta-1b; IVIG = IV immunoglobulins; S1P inhibitors = fingolimod and siponimod; VTE = venous
thromboembolism.
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